SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Capital Expenditures
SCI Pharmtech Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Capital Expenditures
-NT$946.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-10%
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Capital Expenditures
-NT$179.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
25%
|
CAGR 10-Years
9%
|
|
![]() |
Formosa Laboratories Inc
TWSE:4746
|
Capital Expenditures
-NT$587.9m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-2%
|
|
![]() |
ScinoPharm Taiwan Ltd
TWSE:1789
|
Capital Expenditures
-NT$280.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
10%
|
|
![]() |
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Capital Expenditures
-NT$1.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-21%
|
|
![]() |
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Capital Expenditures
-NT$601.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-17%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Capital Expenditures?
Capital Expenditures
-946.6m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Capital Expenditures amounts to -946.6m TWD.
What is SCI Pharmtech Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-10%
Over the last year, the Capital Expenditures growth was 8%. The average annual Capital Expenditures growth rates for SCI Pharmtech Inc have been -7% over the past three years , -36% over the past five years , and -10% over the past ten years .